HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-29-2020, 03:37 PM   #1
Nguyen
Senior Member
 
Join Date: Nov 2005
Posts: 503
Treatment After Progression on CDK 4/6i in mBC

Not really appropriate title, but there are useful info in it.

Nguyen



https://www.onclive.com/view/treatme...sion-on-cdk4-6
Nguyen is offline   Reply With Quote
Old 06-05-2020, 09:28 AM   #2
Nguyen
Senior Member
 
Join Date: Nov 2005
Posts: 503
Re: Treatment After Progression on CDK 4/6i in mBC

Therapy After Cyclin-Dependent Kinase Inhibition in Metastatic
Hormone Receptor-Positive Breast Cancer: Resistance
Mechanisms and Novel Treatment Strategies

https://acsjournals.onlinelibrary.wi...02/cncr.32931c

Endocrine therapy has been the standard of care for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast
cancer since the 1970s, improving survival while avoiding the toxicities associated with cytotoxic chemotherapy. However, all HR-positive
tumors ultimately develop resistance to endocrine therapy. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have more recently
become an important component of the management of this breast cancer subtype, significantly delaying time to the disease progres-
sion and improving survival when combined with endocrine therapy. However, as with endocrine therapy alone, treatment resistance
remains a universal phenomenon. As more women receive CDK4/6 inhibitors as part of their treatment, the management of de novo
and acquired resistance to combined CDK4/CDK6 inhibitor plus endocrine therapy regimens has emerged as an important clinical chal-
lenge. Several resistance mechanisms have been described, including alterations in the CDK4/6/cyclin D complex or its major effector
retinoblastoma protein(pRb), bypass signaling through other cyclin/CDK complexes and activation of upstream signaling pathways,
in particular the PI3K/mTOR pathway, but robust biomarkers to predict resistance remain elusive, and the role for continuing CDK4/6
inhibitors after progression remains under investigation. Novel strategies being evaluated in clinical trials include the continuation of
CDK4/6 inhibitors through progression, as well as triplet therapy combinations with PI3K inhibitors or immune checkpoint inhibitors.
Cancer 2020;0:1-17. © 2020 American Cancer Society.
Nguyen is offline   Reply With Quote
Old 07-27-2021, 08:17 AM   #3
Nguyen
Senior Member
 
Join Date: Nov 2005
Posts: 503
Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?

Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?

https://ascopost.com/issues/april-25...tment-is-best/
Nguyen is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 04:23 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter